AtriCure (NASDAQ:ATRC) Posts Earnings Results, Beats Expectations By $0.10 EPS

AtriCure (NASDAQ:ATRC) posted its earnings results on Tuesday. The medical device company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.10, FiscalAI reports. The company had revenue of $140.50 million for the quarter, compared to the consensus estimate of $140.50 million. AtriCure had a negative return on equity of 1.17% and a negative net margin of 2.14%.The firm’s revenue for the quarter was up 13.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.33) earnings per share.

Here are the key takeaways from AtriCure’s conference call:

• AtriCure closed 2025 with $534.5M revenue (+15%), $61.8M adjusted EBITDA and $45M cash generated, and reaffirmed 2026 guidance of $600–610M (12%–14% growth) with an adjusted EBITDA target of $80–82M, signaling stronger profitability and cash generation.
• New product traction drove growth — launches like cryoSPHERE MAX, AtriClip FLEX/PRO MINI, EnCompass clamp and CryoXT contributed to outsized gains (pain management +33% worldwide; open appendage +19%) and supported modest gross margin expansion.
• Clinical progress is a strategic catalyst — the randomized LEAPS trial completed enrollment (~6,500+ patients) and the BOX X NoAF 960‑patient trial is underway, which the company says could materially expand the addressable market and shift standards of care (timing of definitive readouts remains uncertain).
• Rapid adoption of PFA is a meaningful headwind to the minimally invasive/hybrid AF franchise, with full‑year MIS revenues down ~26% worldwide and the company expecting continued, albeit moderated, pressure in 2026.
• International reimbursement pressures, especially in the U.K., caused a notable Q4 decline (UK run‑rate fell from ~$4M/quarter to ~ $1M), and management expects UK uncertainty to persist through 2026, weighing on near‑term international growth.

AtriCure Trading Down 2.2%

Shares of AtriCure stock opened at $32.26 on Thursday. The company has a quick ratio of 2.85, a current ratio of 3.87 and a debt-to-equity ratio of 0.15. AtriCure has a 12-month low of $28.29 and a 12-month high of $43.18. The company has a market capitalization of $1.60 billion, a price-to-earnings ratio of -134.42 and a beta of 1.41. The firm’s 50-day moving average price is $38.59 and its two-hundred day moving average price is $36.77.

Insider Transactions at AtriCure

In related news, insider Justin J. Noznesky sold 5,166 shares of the company’s stock in a transaction on Wednesday, November 26th. The stock was sold at an average price of $37.29, for a total transaction of $192,640.14. Following the completion of the sale, the insider directly owned 78,798 shares in the company, valued at $2,938,377.42. This represents a 6.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Maggie Yuen sold 3,000 shares of AtriCure stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $35.72, for a total value of $107,160.00. Following the completion of the transaction, the director owned 11,371 shares in the company, valued at approximately $406,172.12. This represents a 20.88% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 18,166 shares of company stock valued at $676,378. Company insiders own 3.50% of the company’s stock.

Institutional Investors Weigh In On AtriCure

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Mackenzie Financial Corp lifted its stake in AtriCure by 5.3% in the 4th quarter. Mackenzie Financial Corp now owns 13,597 shares of the medical device company’s stock valued at $545,000 after purchasing an additional 683 shares during the last quarter. XTX Topco Ltd increased its holdings in shares of AtriCure by 88.0% during the fourth quarter. XTX Topco Ltd now owns 11,069 shares of the medical device company’s stock worth $438,000 after buying an additional 5,182 shares in the last quarter. Susquehanna Portfolio Strategies LLC bought a new position in shares of AtriCure in the 4th quarter valued at $3,415,000. Engineers Gate Manager LP boosted its holdings in shares of AtriCure by 104.2% during the 4th quarter. Engineers Gate Manager LP now owns 58,479 shares of the medical device company’s stock valued at $2,313,000 after acquiring an additional 29,839 shares in the last quarter. Finally, AQR Capital Management LLC grew its position in AtriCure by 18.8% during the 4th quarter. AQR Capital Management LLC now owns 99,956 shares of the medical device company’s stock worth $3,954,000 after acquiring an additional 15,784 shares during the last quarter. 99.11% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ATRC has been the topic of a number of research reports. BTIG Research reaffirmed a “buy” rating and issued a $54.00 price objective on shares of AtriCure in a report on Wednesday. Needham & Company LLC restated a “buy” rating and issued a $45.00 price target on shares of AtriCure in a research note on Thursday, February 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AtriCure in a research report on Wednesday, January 21st. JPMorgan Chase & Co. cut shares of AtriCure from an “overweight” rating to a “neutral” rating and set a $36.00 price objective for the company. in a research note on Wednesday, February 11th. Finally, Canaccord Genuity Group decreased their target price on shares of AtriCure from $64.00 to $53.00 and set a “buy” rating on the stock in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $48.43.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.